Wilex reports completion of Phase I dose escalation trial of cancer drug

Twenty-five patients were treated with the combination of both substances. Patients have received once weekly infusions of WX-UK1 for three weeks at various fixed doses and daily capecitabine concomitantly for two weeks. This three-week cycle was repeated until progression or toxicity. The maximum number of treatment cycles was 15 (eleven months). Twenty-three patients completed at least one treatment course with an average of 4.5 treatment courses.

The combination therapy was safe and well tolerated. The typical capecitabine-related adverse events were observed and no apparent changes in the frequencies or intensities of these side effects were reported. No serious adverse events related to WX-UK1 were reported.